BiomX (NYSEMKT:PHGE) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of BiomX (NYSEMKT:PHGE) in a report issued on Tuesday, Benzinga reports. HC Wainwright currently has a $2.00 price target on the stock.

BiomX Stock Performance

Shares of PHGE opened at $0.34 on Tuesday. The firm’s 50-day moving average price is $0.36 and its 200 day moving average price is $0.32. The stock has a market capitalization of $19.04 million, a P/E ratio of -0.65 and a beta of 1.31. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.51.

Hedge Funds Weigh In On BiomX

An institutional investor recently bought a new position in BiomX stock. Ikarian Capital LLC acquired a new stake in shares of BiomX Inc. (NYSEMKT:PHGE) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,817,327 shares of the company’s stock, valued at approximately $4,868,000. Ikarian Capital LLC owned 19.59% of BiomX as of its most recent SEC filing. Hedge funds and other institutional investors own 40.57% of the company’s stock.

About BiomX

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).